Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study

Michèle Cavo; Francesca Gay; Meral Beksaç; Lucia Pantani; Maria Teresa Petrucci; Meletios Α. Dimopoulos; Luca Dozza; Bronno van der Holt; Sonja Zweegman; Stefania Oliva; Vincent H. J. van der Velden; Elena Zamagni; Giuseppe A. Palumbo; Francesca Patriarca; Vittorio Montefusco; Mónica Galli; Vladimír Maisnar; Barbara Gamberi; Markus Hansson; Angelo Belotti; Luděk Pour; Paula F. Ypma; Mariella Grasso; Alexsandra Croockewit; Stelvio Ballanti; Massimo Offidani; Iolanda Donatella Vincelli; Renato Zambello; Anna Marina Liberati; Niels Frost Andersen; Annemiek Broijl; Rossella Troia; Anna Pascarella; Giulia Benevolo; Mark‐David Levin; Gerard M.J. Bos; Heinz Ludwig; Sara Aquino; Anna Morelli; Ka Lung Wu; Rinske Boersma; Roman Hájek; Marc Durian; Peter A. von dem Borne; Tommaso Caravita di Toritto; Thilo Zander; Christoph Driessen; Giorgina Specchia; Anders Waage; Peter Gimsing; Ulf‐Henrik Mellqvist; Marinus van Marwijk Kooy; Monique C. Minnema; Caroline M.P.W. Mandigers; Anna Maria Cafro; Angelo Palmas; Susanna Carvalho; Andrew Spencer; Mario Boccadoro; Pieter Sonneveld

doi:10.1016/s2352-3026(20)30099-5

April 30, 2020The Lancet HaematologyOpen Access

Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study

View Full Paper

Ask AI

Bookmark

Share

Key Points

To compare autologous haematopoietic stem-cell transplantation with bortezomib–melphalan–prednisone, alongside bortezomib–lenalidomide–dexamethasone consolidation and lenalidomide maintenance, in newly diagnosed multiple myeloma.
Study (EMN02/HO95) in patients with newly diagnosed multiple myeloma.
Assessed high-dose intensification using autologous haematopoietic stem-cell transplantation compared with bortezomib–melphalan–prednisone chemotherapy.
Evaluated subsequent randomization to bortezomib–lenalidomide–dexamethasone consolidation therapy versus no consolidation, followed by continuous lenalidomide maintenance.
Assessed the comparative efficacy and progression-free survival between autologous haematopoietic stem-cell transplantation and standard bortezomib-based chemotherapy combinations.
Evaluated the therapeutic benefit of post-induction consolidation therapy with bortezomib, lenalidomide, and dexamethasone prior to long-term lenalidomide maintenance.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Evaluates stem-cell transplantation versus chemotherapy regimens in newly diagnosed multiple myeloma, indicating key strategies for intensification and maintenance therapy.

Abstract

Janssen and Celgene.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Cavo et al. (2020) studied this question.

synapsesocial.com/papers/69d768afdb2079ce7048f3c6 https://doi.org/10.1016/s2352-3026(20)30099-5

View Full Paper

Ask AI

Bookmark

Share

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading